

Apcotex Industries

"Growth Chemistry"





Textile Finishing & Non Woven

Bonding & Waterproofing in Construction

Brakes & Jointing Sheets



Apcotex Industries

Sector: Specialty Chemicals

"Growth Chemistry"

Financial Summary

Y/E March	Net Sales (Rs Cr)	EBITDA (Rs Cr)	PAT (Rs Cr)	EPS (Rs)	Change (%)	P/E (x)	RoE (%)	RoCE (%)	EV/EBITDA (x)	DPS (Rs)
FY18	538	64	39	18.6	10.4	26.6	15.6	18.7	15.9	6.0
FY19E	616	77	45	21.8	17.4	24.5	16.0	18.5	14.5	8.2
FY20E	731	96	61	29.5	35.4	18.1	18.4	20.7	11.0	11.1

Source: Company, Axis Securities, CMP as on Dec 19, 2018

20 Dec 2018

Company Report

Buy

Target Price: Rs. 664

CMP : Rs. 534 Potential Upside : 24%

MARKET DATA

: 2.08 Cr. No. of Shares Market Cap : Rs. 1,105 Cr.

: 42.08% Free Float

Avg. daily vol (6mth) : 4,431 52-w High / Low : 668/440 Bloomberg : APCO IN Promoter holding : 57.9% : 0.47% DII

Price performance



Key Drivers %

Growth (%)	FY18	FY19E	FY20E
Synthetic Rubber Vols	15.4	11.1	22.4
Net Sales	24.9	14.5	18.6
EBITDA Margin	11.9	12.5	13.2
PAT	10.4	17.4	35.4





Investment Rationale

Apcotex Industries Ltd

Sector: Specialty Chemicals

Leading player in Emulsion Polymer segment a niche product segment

- Formidable positioning in the emulsion polymer industry given that Apcotex Industries Ltd. (AIL) has +30 years of experience
- Numero uno position in paper (42% share), carpet (65% share), construction (35%) and tyre (25%) industry for Synthetic Latex products
- Healthy volume growth of 13.5% CAGR over the last decade (FY09-18). We expect total volumes to grow at 13% CAGR over FY18-20E

NBR Market a huge opportunity

- Single largest and only player in India manufacturing Nitrile Butadiene Rubber (NBR)
- Global market estimated to be ~5,00,000MT entailing huge opportunity to incrementally grow exports market
- NBR market in India stands at ~40,000MT growing at 6-8% CAGR, while 80% NBR is imported
- AIL a market leader with 20% market share an increase of 400bps over FY16-FY18 following acquisition of Omnova Solutions. Import substitution offers huge opportunity to grow market share in high margin NBR product
- To incur Rs. 70 crore (Phase I) efficiency improvement capex at Valia plant (NBR focused) to undertake de-bottlenecking of manufacturing process and improve asset turnover. Of this Rs. 30 crore to be spent in FY19

Significantly higher entry barriers

- Handling explosive, toxic and inflammable RMs is critical, AIL has experience and expertise which is difficult to replicate
- Elongated customer approval cycles between 6 months to 3 years
- Critical process technology developed in-house allows sustainable competitive edge
- Developing proprietary products ensures product customization and thus client stickiness and loyalty



Investment Rationale

Apcotex Industries Ltd

Sector: Specialty Chemicals

New Product foray (X-NBR) prime growth driver

- X-NBR Latex (Carboxylated NBR / Nitrile Latex) for gloves used in medical, surgical and industrial applications; AIL the only Indian manufacturer
- Low per capita consumption in countries outside NAFTA and EU which consume ~80% of manufactured gloves
- Market size is ~5–6 lakh MTPA in South East Asia; Apcotex has a Latex capacity of 55,000 tons with capex to expand Latex product in the pipeline over next 2-3 years
- Export market a huge target market for X-NBR Latex used in manufacturing gloves (medical, examination, industries)
- 80% of medical glove production is located in Asia with Malaysia being the largest producer with 69% production share

Net Debt free balance sheet allows taking leverage for growth capex

- Omnova Solutions acquisition of Rs. 30 crore in FY2016 was fully funded from internal accruals
- Management's core philosophy of self sustainability aided maintaining a net-debt free balance sheet as average gross Debt-Equity ratio has been 0.1x in FY18. This leaves enough scope to leverage balance sheet for growth capex
- However, strong CFO over FY19 and FY20E (Rs. 139.2 crore) will ensure undertaking capex without strain on return ratios
- Expect AIL to report ROE of 16.0%/18.4% in FY19E/FY20E as against 13.2% reported in FY16

Strong Operating Performance; to aid Earnings CAGR of 26% over FY18-FY20E

- We expect Apcotex Industries to post Revenue/EBITDA/Earnings CAGR of 17%/23%/26% respectively over FY18-FY20E led by
 - o Strong market share, new product launches, growing NBR revenue contribution, working capital efficiency and sticky clientele
- Reported an earnings CAGR in excess of 30% over FY14-FY17, we estimate the trajectory to continue
- Consistent ROE improvement to 15.6% in FY18 over FY16; momentum to sustain in FY19E/FY20E with 16%/18.4% ROE
- We initiate coverage on Apcotex Industries with "BUY" rating & target price of Rs. 664 / share; upside 24% over 12 months



Company Brief

Apcotex Industries Ltd

Sector: Specialty Chemicals

Background

Established in 1981 as a unit of Asian Paints, the largest paint manufacturer in India. However, in 1991 Apcotex Industries Limited (AIL) was spun-off as a separate listed entity headed by Mr. Atul Choksey, now Chairman of the company and a former Managing Director of Asian Paints. AlL pioneered production of Vinyl Pyridine Latex (VP Latex) an important raw material for Tyre industry in India. AlL is the only manufacturer of X-NBR in India launched in 2018.

Products

- Synthetic Latex (VP Latex, Nitrile Latex, XSB & Acrylic Latex)
- Synthetic Rubber (NBR & HSR):
- ApcoBuild: Own brand catering to waterproofing and construction industry, a B2B focused business

End User Industry

Synthetic Latex and Synthetic Rubber find application in industries like Tyre Cord Dipping, Paper/Board Coating, Carpet Backing, Construction (Concrete Modification, Water Proofing, etc.), Paints, Textile Finishing and Automotive Components. High Styrene Synthetic Rubber finds applications in footwear, automotive components, v-belts, conveyer belts and hoses.

R&D

 Developed a strong R&D base, which enabled it to develop new products and compete against global players such as BASF and Dow Chemicals not only in India but also by entering in export markets

In-organic Growth

In February 2016, AlL acquired 100% stake in Omnova Solutions India Pvt Ltd (OSIPL), the Indian arm of US-based specialty company Omnova Solutions Inc, then a leader in manufacturing NBR and HSR with manufacturing plant at Valia, Gujarat. The deal was for Rs. 30 crore entirely funded from internal accruals. The acquisition is aligned to Apcotex' long term strategy to tap the full potential of the emulsion polymers industry





Company Leadership & Management

Apcotex Industries Ltd

Sector: Specialty Chemicals

Chairman

Founder & Promoter of Apcotex Industries when it was spun-off as a unit of Asian Paints, Mr. Atul Choksey a Chemical Engineer from Illionis Institute of Technology, Chicago, USA. He has than three more decades of experience in managing the affairs of AIL. Is on the board various reputed companies like Marico, Ceat and Finolex Cables

Managing Director

He is a Bachelor of Science in Economics from Wharton Business School and also Bachelor of Science in Engineering from the School. Engineering both of University of Pennsylvania in U.S.A. Mr. Abhiraj Choksey is the driving force for the company and an able leader

Executive Director

A Chemical Engineer. With three over decades experience of working with Apcotex Industries and Asian Paints since 1981. Mr. Gadgil is actively involved in handling the Operations, Production, Projects, Engineering, Supply Chain and other Factory administration related functions Apcotex Industries.

Company Secretary

Associated with Apcotex Industries over the last two decades. Mr. Kumashi is actively involved in functions of the company which includes Accounts, Finance and Compliance.

Mr. Atul Choksey

Mr. Abhiraj Choksey

Mr. Yashodhan Gadgil

Mr. Anand Kumashi





Key Milestones

Apcotex Industries Ltd

Sector: Specialty Chemicals

Started as division of Asian Paints (I) Ltd & pioneered the manufacture of Vinyl Pyridine latex & CarboxylatedStyrene-Butadiene latex

Started Synthetic Rubber production with 10,000 MT (Dry) capacity

O

Installed capacity of saleable latex increased from 40,000 MT/Annum to 55,000 MT/Annum (wet)

0


2013

Introduced new product

- X-NBR

(used in medical &
examination gloves), the
1st company in the
Indian markets to foray
into this segment

2018



Spun off from Asian Paints and listed on

Asian Paints and listed on stock exchanges as Apcotex Lattices Limited (now Apcotex Industries Ltd.). Spun-off entity led by Mr. Atul Choksey then MD of Asian Paints (India) Ltd. Started Acrylic emulsion to exploit synergies with other products and markets

2009

Acquired Omnova Solutions Pvt Ltd. for Rs. 30cr leader in NBR and HSR segment

2016






Manufacturing Presence a locational advantage


Apcotex Industries Ltd

Sector: Specialty Chemicals



Plant **Product** Capacity Location Synthetic Latex Taloja 55,000 High Styrene Rubber (HSR) Taloia 7,000 Nitrile Butadiene Rubber (NBR) & Valia 16,000 **Allied Products Total Installed Capacity** 78,000

Manufacturing Capacity





HIGH STYRENE RUBBER



Key Products: Synthetic Latex & Synthetic Rubber

Apcotex Industries Ltd

Sector: Specialty Chemicals



Synthetic Rubber

Source: Company, Axis Securities

NBR POWDER




Synthetic Latex: Marquee Clientele

Apcotex Industries Ltd

Sector: Specialty Chemicals

Clientele		Key Industry	End Use Application	Revenue Share(%)	Growth Trends	Key Competitors
ITC Limited PAPER	bilt	Paper	Provides binding strength (wet and dry), adds gloss and coating holdout	25%		I-BASF TRINSEO.
ANALY Of the office of the original	ABC	Carpet	Chemical additives for textile floorings, synthetic turf, mattresses, secondary backing for tufted carpets etc	15%		I-BASF TRINSEO.
FOSROC	Pidilite	Construction	Waterproofing, bonding agent for cement, sand plaster on concrete and Gypsum	12%		I-BASF TRINSEO.
SRF	MRF	Tyre Cord	Tyre cord, belting fabric dipping	10%	Low growth (used in bias tyres)	JUBILANT INDUSTRIES
N.A.T.		Specialty	Binder for non-woven Fabric, paper saturation, binder for cork sheet, textile finishing, adhesives	12%	Steady	
Exported : Malaysia	Thailand	Gloves	Medical & Industrial purposes	Newly launched	High growth area	







Synthetic Rubber: Marquee Clientele

Apcotex Industries Ltd

Sector: Specialty Chemicals

Clientele	Key Industry	End Use Application	Revenue Share(%)	Growth Trends	Key Competitors
Jayashree Polymers	Nitrile Rubber (NBR)	For brakes & jointing sheets, automotive components, LPG Tubing, rubber component Manufacturers	70%	High growth area	KUMHO PETROCHEMICAL
VANH INDUSTRIES WE RESPICT TO AN ARLES	NBR Polyblend	For manufacture of Rice Rolls & Hoses	5-10%	Steady	-
GROUP, s.r.o.	NBR Powder	Jointing sheets, PVC modifications, medium CAN grade for footwear, adhesives, friction material, brake pads,	5-10%	High growth area	-
Ajanta Since 1956 Paragon	High Styrene Rubber (HSR)	Manufacturing of Hawai Chappal, micro cellular solings, floor tiles, battery boxes etc	15%	Stagnant	IMPORT






Market Opportunity – Emulsion Polymerization Chemistry

Apcotex Industries Ltd

Sector: Specialty Chemicals


- ◆ Synthetic Latex ~45% revenue share
 - Apcotex Industries is among the leading players in the emulsion polymer industry with over 30 years of experience
- Qualities: water resistance, strength, flexibility
- Market Size:
 - ✓ Domestic market ~1,20,000 MT; 8-10% CAGR over FY08-18
 - ✓ AlL's capacity 55,000 MT which is 45.8% in total domestic industry share
- Peers: BASF, Dow Chemicals, Jubilant Industries, imports from Europe & Asia

Synthetic Latex: Market Share



- End User Industry growth prospects
 - Paper & Paper board: improving demand and earnings outlook augurs well for AlL's Synthetic Latex segment
 - Water Proofing / Construction: both concrete admixture and water proofing segments expected to grow ~15% driven by infrastructure, affordable housing and construction/ infra push by Government
 - Carpet: with US and Europe being key end user markets and reporting steady growth, carpet industry too is likely to report steady growth
 - Tyre Cord: with healthy demand forecast for CV industry volumes, AIL too would benefit as Synthetic Latex is used in non-radial tyres which are found in CVs

FY18 Revenue Contribution: Industry wise










Market Opportunity – Emulsion Polymerization Chemistry

- **Apcotex Industries Ltd**
- Sector: Specialty Chemicals

- Nitrile Rubber − ~40% revenue share
- Also called as Acrylonitrile Butadiene Rubber
- Qualities: heat resistant, used primarily for oil resistance
- ♦ Market Size :
 - ✓ Domestic: ~40,000MT; 8-10% CAGR growth over FY08-18
 - ✓ Global ~5,00,000MT; 5-7% CAGR growth over FY08-18
 - ✓ AlL's capacity ~16,000 MT
- Peers: Kumho Petrochemicals, Korea
- AlLs Market Share: 20% in domestic market (FY16 @18%)



Apcotex Industries to gain substantially from Import substitution (c80% imported)

- ◆ High Styrene Rubber (HSR) 15% revenue share
- A special variety of Styrene Butadiene Rubber (SBR)
- Qualities: improve hardness, aging resistance, improves tear and tensile strength of rubbers and electrical insulation
- Market Size:
 - ✓ Domestic: ~8,000MT and stagnant growth (earlier 15,000MT) due to change in customer preference towards more trendy and aesthetically looking footwear / slippers / footwear
 - ✓ AlL's capacity 7,000MT
- Peers: None in Domestic market

AlL became largest manufacturer in India post acquisition of erstwhile Omnova Solutions (India) Pvt. Ltd.





Omnova Solutions: A Strategic Acquisition

Sector: Specialty Chemicals

Apcotex Industries Ltd

◆ Feb 2016, acquired 100% stake in Omnova Solutions (India) Pvt Ltd, arm of US based Omnova Solutions for Rs. 36 crore, completely funded from internal accruals


Acquisition rationale:

- ✓ Allowed tapping long term growth potential in Emulsion Polymer industry (115 acres land at Valia)
- ✓ Expanded capacities NBR (12,000MTPA), HSR (8,000MTPA), NBR PVC/PVC Powder (4,000MTPA)
- ✓ Diversified end user industry automotive, LPG Tubing, Wires & Cables
- ✓ Became the largest player of NBR and HSR products in India
- √ OSIPL enjoyed 18% market prior to acquisition. The same now has improved to 20% for AIL with whom OSIPL has merged completely


• Successful turnaround of inefficient Omnova Solutions operations visible in :

- ✓ Improved Cash Conversion Cycle from 122days to 58 days now over FY16-FY18
- ✓ Efficiency in RM procurement and lowering operating costs
- \checkmark Expansion in EBITDA Margins from 6% to 12% now over FY16-18
- ✓ Improved capacity utilization aided by capex of Rs. 70 crore (Phase-I) towards de-bottlenecking, operational efficiency etc at Valia plant

Sharp reduction in Cash Conversion Cycle



EBITDA Margin expansion (+600bps) aided by operating efficiency







NBR Market a huge opportunity


- Apcotex Industries Ltd
- Sector: Specialty Chemicals

- Single largest and only player in India manufacturing NBR
- Global market estimated to be ~5,00,000MT entailing huge opportunity to incrementally grow the exports market
- NBR market in India stands at ~40,000MT growing at 6-8% CAGR
- All sweetly positioned to take share from imports (c80%)
- AlL a market leader with 20% market share which has increased by 400bps over FY16-FY18 following acquisition of Omnova Solutions and its facility at Valia
- Incurred Rs. 30 crore (Rs. 70crore Phase I capex) towards efficiency improvement at Valia plant (NBR focused) to undertake de-bottlenecking of manufacturing process and improve asset turnover


Focus on exports to boost revenue outlook

- Strong product portfolio, newly launched product XNBR, innovative, higher margin products in the pipeline a huge potential to grow exports revenue
- Healthy demand witnessed in export markets for Tyre Latex, Carpet Latex, Textile Latex, Construction Latex.
 NBR and X-NBR ensure large export revenue opportunity
- Exports reported 26% CAGR over FY11-18; FY18 exports contributed ~10% of Total Revenues
- Management intends to increase export revenues to 25% over next 5 years

Source: Company, Axis Securities



Exports to provide a fillip for Revenue Growth





■ Malaysia

■ Thailand

■ Sri Lanka

■ Indonesia

■ Vietnam

Others (USA,

Europe, Mexico)

■ China / Taiwan




New Product foray (X-NBR) prime growth driver


- X-NBR Latex (Carboxylated Nitrile Rubber Latex) for gloves is used in medical, surgical and examiniation gloves. It also finds application in industrial applications like mining, construction, manufacturing etc
- Apcotex Industries the only Indian manufacturer to produce X-NBR (Carboxylated Nitrile Rubber)
- Low per capita consumption in countries outside NAFTA and EU which consume ~80% of manufactured gloves
- Market size is ~6-7 lakh MTPA in South East Asia;
 Apcotex has a Latex capacity of 55,000 tons with capex to expand Latex product over next 2-3 years
- Export market a huge target market for X-NBR Latex used in manufacturing gloves (medical, examination, industries)
 - ✓ Total addressable market size of Nitrile Gloves Latex in Europe ~Rs. 2,200 Cr
 - ✓ Synthomer 2nd largest player globally with 60% share
 - √ Top 5 global manufacturers reported ~13% revenue CAGR over FY10-17
- Strong demand for NBR & X-NBRR (health awareness, decline in demand for Natural Rubber gloves which causes allergies), management highlighted undertaking a capex of ~Rs 230-250 crore to aid in capacity expansion for NBR of 15,000 tons and Synthetic Latex ~40,000tons. Greenfield capex to commence beyond FY20



Sector: Specialty Chemicals



End User Industries: Gloves







Significantly Higher Entry Barriers

Apcotex Industries Ltd

Sector: Specialty Chemicals

RM Handling Butadiene, Acrylic Acid Acrylonitrile, Styrene and VP Monomer are explosive, toxic and inflammable products and needs special handling which AIL has developed expertise in over the period

High Entry Barriers Approval Time

Customer approval cycles are elongated and takes anywhere between 6 months to 3 years to provide commercial supplies. Latex products manufactured by AIL forms 2-10% of end product

Process Technology Critical process technology developed in-house allows sustainable competitive edge as emulsion polymers are complex products

Proprietary Products

Developing proprietary products ensures product customization (varied grades of latex) and thus client stickiness and loyalty



Apcotex Industries Ltd


Sector: Specialty Chemicals



Financial Commentary


- ◆ Revenue CAGR 16.5% over FY18-FY20E driven by improving product mix:
 - 25% topline growth reported in FY18 led by strong growth in NBR and steady business from latex segment.
 - Latex to report steady 8-10% growth backed by paper & waterproofing segment
 - NBR to be a key growth driver in our view:
 - ✓ Contribution to improve to ~44% by FY20E from 40% in FY18 driven by launch of X-NBR (new product) used in medical & industrial gloves
 - ✓ Healthy new product launch pipeline
 - ✓ 25% capacity addition in NBR

EBITDA Margin expansion of 650bps over FY17



Source: Company, Axis Securities

Topline growth of 16.5% CAGR over FY18-20E



- Margin expansion on the card aided by better utilization and growing share of higher margin NBR
 - Following acquisition of Omnova Solutions in FY16, EBITDA Margins contracted to historic lows of 6.7% led by inefficiencies in acquired company.
 - 520bps expansion in EBITDA Margins to 11.9% in FY18 over FY16 due to :
 - ✓ Turnaround in loss making Omnova Solutions
 - ✓ Improved capacity utilization at Valia and Taloja plants
- H1FY19 EBITDA Margin at 12.1% despite RM volatility. This
 was due to new product launch (Carboxylated NBR used in
 medical gloves), growing revenue share of higher margin
 NBR and improved capacity utilization.
- Expect utilization levels to improve to 85% by FY20E rom 75% in FY18





Financial Commentary

Company Report

Apcotex Industries Ltd


Sector: Specialty Chemicals

Earnings CAGR of 26% over FY18-20E


- AlL reported 15% PAT CAGR over FY15-18 impacted by workmen strike, Omnova Solutions integration and slower offtake from key clients (BILT)
- Going ahead, over FY18-20E we expect the company to report 26% PAT CAGR aided by better product mix, improved operating efficiency and new product launches

Efficient capital allocation to ensure Return Ratios remain healthy


- Apcotex Industries has a net-debt free balance sheet as of FY18. Thus it allows enough room to leverage its balance sheet for growth capex
- Despite this, we expect the company to report healthy ROEs of 16.0%/18.4% in FY19/FY20E from 13.2% reported in FY16 aided by better operating profit (net margin to improve to 8.4% in FY20E from 7% in FY15)



Consistent Earnings growth aided by new products & exports



Healthy Return Ratios to be maintained despite capex







Financial Commentary


Apcotex Industries Ltd

Sector: Specialty Chemicals

Strong balance sheet allows scope to leverage for growth capex

- Apcotex Industries has maintained strong balance sheet despite healthy growth in capacity creation. Its Net Debt-Equity ratio remained in the range of 0.15x-0.07x from FY15-FY18
- Expect cash flows to improve over FY18-FY20E aided by improved operating performance and higher margins products
- We expect the company to become a totally debt free company over FY19E / FY20E from 0.15x in FY15

Net-debt free balance sheet - a key advantage




Source: Company, Axis Securities

WC efficiency driven by healthy reduction in Debtor & Inventory days

- Following acquisition of Omnova Solutions in FY2016 Debtor Days increase sharply from 50 days in FY15 to 90 days in FY16.
 In FY18 it stood at 60 days a sharp reduction owing to Management's focus on improving working capital efficiency
- Inventory days too declined from 61 days in FY16 to 47 days in FY18 aided by dynamically managing RM procurement
- Expect a significant improvement in Net Working Capital to 37days in FY20E from 95 days reported in FY16 and 58 days in FY18

Significant improvement in Working Capital Efficiency







Peer Comparison

Apcotex Industries Ltd

Sector: Specialty Chemicals

	As o				C,	Y2018				ī	TM	FY2	019E
	Market Cap (Full) Rs. Cr	СМР	Net Sales (Rs.cr)	YoY Sales (%)	EBITDA Margin	PAT (Rs. cr)	Debt: Equity (x)	ROE (%)	ROA (%)	P/E	EV/ EBITDA	P/E	EV/ EBITDA
Apcotex Industries*	1,105	534	538	25	12.2%	39	0.07	16.5	12.0	23.8	14.4	21.1	13.3
Synthomer	10,889	359	12,766	46	11.8%	638	0.70	20.7	6.5	12.1	8.0	11.2	7.8
Trinseo	13,447	45	28,392	12	11.8%	2,096	1.74	59.2	12.8	4.8	4.9	5.4	4.3
Celanese	80,742	85	39,192	7	20.8%	5,381	1.26	34.6	10.6	8.3	8.9	7.7	6.6
Nantex	3,216	28	2,506	26	12.4%	175	0.02	12.0	10.3	9.5	5.3	-	-

Source : Company; Axis Securities Research; Reuters, Apcotex Industries data is as of FY2018





Apcotex Industries Ltd

Sector: Specialty Chemicals



Outlook & Valuations





Source: Company, Axis Securities

Valuation

- ♦ We estimate Apcotex Industries to post Revenues/Earnings CAGR of 16.5% / 26% respectively over FY18-FY20E
- We expect the company to report EBITDA Margin of ~12.5% / 13.2% over FY19E/FY20E an expansion of 650bps over from 6.7% reported in FY17
- ROEs are estimated to increase to +18% over FY18-FY20E
- We value Apcotex Industries at 22.5x FY20E EPS given the growth prospects and arrive at a TP of Rs. 664 (24% Upside)

Risk Factors

- Volatility in key petrochemical prices like Acrylonitrile, Styrene and Butadiene which forms ~65-70% of total RM costs. AlL is insulated from the same given the complete pass through to customers
- Dependence on any single customer to impact volume growth
- Growth slowdown in key end user industries
- Delay in capacity expansion
- Forex volatility
- Stringent environmental pollution related regulations





Financials

Apcotex Industries Ltd

Sector: Specialty Chemicals

Profit & Loss (Rs Cr)

	FY17	FY18	FY19E	FY20E
Total Net Sales	431	538	616	<i>7</i> 31
% Change	60.6%	24.9%	14.5%	18.6%
Total Raw material Consumption	269	361	419	501
Staff costs	29	34	13	16
Other Expenditure	104	80	107	118
Total Expenditure	402	474	539	634
EBITDA	29	64	77	96
% Change	-22.4%	119.5%	20.8%	25.2%
EBITDA Margin %	6.7%	11.9%	12.5%	13.2%
Depreciation	12.1	12.1	19.6	21.4
EBIT	1 <i>7</i>	52	57	75
% Change	-40.5%	204.5%	11.1%	30.8%
EBIT Margin %	3.90%	9.60%	9.30%	10.30%
Interest	3	2	2	2
Other Income	30	7	9	15
(as % of PBT)	69%	13%	14%	17%
PBT	43	56	65	88
Tax	8	17	19	26
Tax Rate %	19.4%	30.7%	30.0%	30.0%
APAT	35	39	45	61
% Change	41.8%	10.4%	17.4%	35.4%

Balance Sheet	(Rs.	(r
Balance Sheet		Rs.	C

	FY17	FY18	FY19E	FY20E
Share Capital	10	10	10	10
Reserves & Surplus	213	236	273	324
Net Worth	223	246	284	334
Total Loan funds	22	1 <i>7</i>	18	19
Deferred Tax Liability	1	2	2	2
Long Term Provisions	2	2	3	3
Other Long Term Liability	4	8	4	5
Capital Employed	252	276	311	363
Gross Block	99	99	174	176
Less: Depreciation	11	21	41	62
Net Block	87	78	134	114
Investments	64	71	71	91
Sundry Debtors	78	98	93	100
Cash & Bank Bal	7	33	15	70
Loans & Advances	0	0	0	0
Inventory	45	49	52	55
Other Current Assets	10	10	11	13
Total Current Assets	140	190	1 <i>7</i> 1	239
Curr Liab & Prov	45	73	76	92
Net Current Assets	94	11 <i>7</i>	95	146
Total Assets	252	276	310	363





Financials

Apcotex Industries Ltd

Sector: Specialty Chemicals

Cash Flows (Rs Cr)

				/
	FY1 <i>7</i>	FY18	FY19E	FY20E
PBT	43	56	65	88
Depreciation & Amortization	12	12	20	21
Provision for Taxes	3	2	2	2
Chg in Deferred tax	-26	-8	0	0
Chg in Working cap	-3	5	1	-15
Diret tax paid	-7	-14	-19	-26
Cash flow from operations	22	53	68	69
Chg in Gross Block	-11	-12	-77	-2
Chg in Investments	-138	-14	0	0
Chg in WIP	141	16	0	0
Cash flow from investing	-8	-10	<i>-77</i>	-2
Proceeds / (Repayment) of Short Term Borrowings (Net)	5	-5	0	0
Repayment of Long Term Borrowings	-8	0	0	0
Loans	0	0	1	1
Finance Cost paid	-3	-2	-2	-2
Dividends paid	-9	-9	-8	-11
Dividend Distribution Tax paid	-2	-2	0	0
Cash flow from financing	-1 <i>7</i>	-18	-9	-12
Chg in cash	-3	25	-18	55
Cash at start	9	6	33	15
Cash at end	6	31	15	70

(%	b))
	(%	(%)

	FY1 <i>7</i>	FY18	FY19E	FY20E
Growth (%)				
Net Sales	60.6%	24.9%	14.5%	18.6%
EBITDA	-22.4%	119.5%	20.8%	25.2%
APAT	41.8%	10.4%	17.4%	35.4%
Per Share Data (Rs.)				
Adj. EPS	16.8	18.6	21.8	29.5
BVPS	107.1	118.4	136.2	160.4
DPS	4.5	6.0	8.2	11.1
Profitability (%)				
EBITDA Margin	6.7%	11.9%	12.5%	13.2%
Adj. PAT Margin	8.1%	7.1%	7.4%	8.4%
ROCE	6.7%	18.7%	18.5%	20.7%
ROE	15.6%	15.6%	16.0%	18.4%
ROIC	9.3%	30.0%	25.5%	37.2%
Valuations (X)				
PER	19.0	26.6	24.5	18.1
P/BV	3.0	4.2	3.9	3.3
EV / EBITDA	23.5	15.9	14.5	11.0
EV / Net Sales	1.6	1.9	1.8	1.5
Turnover Days				
Asset Turnover	3.0	5.4	4.5	4.2
Inventory days	59.5	47.5	44.0	38.8
Debtors days	68.6	59.8	56.6	48.2
Creditors days	46.1	49.6	55.5	50.8
Working Capital Days	82.0	57.7	45.1	36.3
Gearing Ratio				
Total Debt to Equity (x)	0.1	-0.1	0.0	-0.2



Disclaimer

Apcotex Industries Ltd

Sector: Specialty Chemicals

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, Suvarna Joshi Senior Manager, Research, MBA (Finance), author/s and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period.

Any holding in stock – No

- 5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
- 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:
 - i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
 - ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
 - iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.





Disclaimer

Apcotex Industries Ltd

Sector: Specialty Chemicals

	DEFINITION OF RATINGS					
RATINGS	Expected absolute returns over 12-18 months					
BUY	More than 10%					
HOLD	Between 10% and -10%					
SELL	Less than -10%					
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation					
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events					
NO STANCE	We do not have any forward looking estimates, valuation or recommendation for the stock					

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai-400070, Tel No. – 18002100808/022-61480808, Regd. off.- Axis House, 8th Floor, Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Anand Shaha, Email: compliance.officer@axisdirect.in, Tel No: 022-42671582.

